Shanghai Junshi Biosciences Co Ltd is a CN-based company operating in Biotechnology industry. The company is headquartered in Shanghai, Shanghai and currently employs 2,578 full-time employees. The company went IPO on 2018-12-24. Shanghai Junshi Biosciences Co Ltd is a China-based company mainly engaged in innovation-driven biopharmaceutical business. The firm's main businesses are the discovery, clinical research and development of innovative drugs. The firm's main products include teriprizumab injection, Etesevimab, adalimumab injection and other drugs, which are used to treat malignant tumors, autoimmune system diseases, chronic metabolic diseases, nervous system diseases and infectious diseases. The firm is also engaged in the clinical research and development of recombinant humanized anti-PCSK9 monoclonal antibody injection and other drugs. The firm provides its products for domestic and overseas markets.
Follow-Up Questions
Who is the CEO of Shanghai Junshi Biosciences Co Ltd?
Ms. Jianjun Zou is the Chief Executive Officer of Shanghai Junshi Biosciences Co Ltd, joining the firm since 2022.
What is the price performance of SHJBF stock?
The current price of SHJBF is $4.22, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Shanghai Junshi Biosciences Co Ltd?
Shanghai Junshi Biosciences Co Ltd belongs to Biotechnology industry and the sector is Health Care
What is Shanghai Junshi Biosciences Co Ltd market cap?
Shanghai Junshi Biosciences Co Ltd's current market cap is $1.1B
Is Shanghai Junshi Biosciences Co Ltd a buy, sell, or hold?
According to wall street analysts, 3 analysts have made analyst ratings for Shanghai Junshi Biosciences Co Ltd, including 1 strong buy, 0 buy, 2 hold, 3 sell, and 1 strong sell
